Kiora Pharmaceuticals, Inc. Logo

Kiora Pharmaceuticals, Inc.

KPRX

(1.8)
Stock Price

3,50 USD

10% ROA

15.57% ROE

4.48x PER

Market Cap.

10.218.658,00 USD

0.25% DER

0% Yield

19.63% NPM

Kiora Pharmaceuticals, Inc. Stock Analysis

Kiora Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kiora Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.14x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

4 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 ROE

The stock's ROE indicates a negative return (-123.45%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-154.16%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Kiora Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kiora Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Kiora Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kiora Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 669.259 100%
2017 407.518 -64.23%
2018 1.652.520 75.34%
2019 2.686.000 38.48%
2020 12.059 -22173.82%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 80.000 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kiora Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 3.034.397
2013 1.010.268 -200.36%
2014 531.116 -90.22%
2015 2.717.110 80.45%
2016 8.422.542 67.74%
2017 10.330.349 18.47%
2018 8.055.763 -28.24%
2019 5.389.357 -49.48%
2020 3.566.045 -51.13%
2021 5.350.264 33.35%
2022 3.448.925 -55.13%
2023 4.340.040 20.53%
2023 5.931.351 26.83%
2024 3.626.720 -63.55%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kiora Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 2.817.851
2013 2.087.637 -34.98%
2014 1.930.967 -8.11%
2015 3.960.498 51.24%
2016 5.593.563 29.2%
2017 4.636.408 -20.64%
2018 4.441.458 -4.39%
2019 4.405.684 -0.81%
2020 4.658.769 5.43%
2021 5.323.649 12.49%
2022 8.277.993 35.69%
2023 5.663.376 -46.17%
2023 4.663.146 -21.45%
2024 6.151.892 24.2%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kiora Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2012 -5.832.027
2013 -3.090.264 -88.72%
2014 -2.459.257 -25.66%
2015 -6.675.404 63.16%
2016 -13.337.977 49.95%
2017 -14.539.387 8.26%
2018 -10.685.855 -36.06%
2019 -6.787.042 -57.44%
2020 -8.156.017 16.78%
2021 -10.627.476 23.26%
2022 -11.628.418 8.61%
2023 3.712.672 413.21%
2023 -8.638.385 142.98%
2024 -9.627.080 10.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kiora Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2014 0 0%
2015 -1.257 100%
2016 -7.753.283 99.98%
2017 -9.922.831 21.86%
2018 -6.403.243 -54.97%
2019 2.681.110 338.83%
2020 -188.162 1524.89%
2021 -227.273 17.21%
2022 -134.028 -69.57%
2023 0 0%
2023 -4.027.037 100%
2024 8.492 47521.54%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kiora Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2012 -6.034.095
2013 -3.879.447 -55.54%
2014 -1.773.992 -118.68%
2015 -8.393.149 78.86%
2016 -13.343.437 37.1%
2017 -13.217.917 -0.95%
2018 -10.811.423 -22.26%
2019 -7.096.696 -52.34%
2020 -8.091.940 12.3%
2021 -16.394.919 50.64%
2022 -13.583.610 -20.7%
2023 -23.051.764 41.07%
2023 -13.044.881 -76.71%
2024 -8.886.584 -46.79%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kiora Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -679
2013 -436 -55.5%
2014 -153 -184.97%
2015 -817 81.27%
2016 -906 9.82%
2017 -556 -62.95%
2018 -183 -205.49%
2019 -89 -104.49%
2020 -71 -27.14%
2021 -68 -2.94%
2022 -19 -277.78%
2023 -3 -500%
2023 -24 87.5%
2024 -2 -1100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kiora Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -5.221.887
2013 -2.957.615 -76.56%
2014 -950.617 -211.13%
2015 -4.459.169 78.68%
2016 -8.424.180 47.07%
2017 -6.505.540 -29.49%
2018 -11.114.512 41.47%
2019 -8.153.833 -36.31%
2020 -7.450.963 -9.43%
2021 -10.951.537 31.96%
2022 -10.428.133 -5.02%
2023 -2.521.097 -313.63%
2023 -9.556.951 73.62%
2024 -3.784.726 -152.51%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kiora Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -5.221.887
2013 -2.957.615 -76.56%
2014 -950.617 -211.13%
2015 -4.459.169 78.68%
2016 -8.413.180 47%
2017 -6.468.541 -30.06%
2018 -10.844.512 40.35%
2019 -8.153.833 -33%
2020 -7.317.169 -11.43%
2021 -10.887.672 32.79%
2022 -10.428.133 -4.41%
2023 -2.521.097 -313.63%
2023 -9.556.951 73.62%
2024 -3.733.439 -155.98%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kiora Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 11.000 100%
2017 36.999 70.27%
2018 270.000 86.3%
2019 0 0%
2020 133.794 100%
2021 63.865 -109.5%
2022 0 0%
2023 0 0%
2023 0 0%
2024 51.287 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kiora Pharmaceuticals, Inc. Equity
Year Equity Growth
2012 -34.813.024
2013 -38.287.624 9.07%
2014 -40.026.213 4.34%
2015 6.086.766 757.59%
2016 -329.421 1947.72%
2017 -1.926.922 82.9%
2018 8.936.267 121.56%
2019 6.622.455 -34.94%
2020 6.999.541 5.39%
2021 9.224.614 24.12%
2022 11.407.600 19.14%
2023 6.109.654 -86.71%
2023 8.103.969 24.61%
2024 33.101.672 75.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kiora Pharmaceuticals, Inc. Assets
Year Assets Growth
2012 2.342.726
2013 692.194 -238.45%
2014 1.406.470 50.79%
2015 9.507.701 85.21%
2016 9.730.602 2.29%
2017 14.305.392 31.98%
2018 14.280.617 -0.17%
2019 10.112.514 -41.22%
2020 15.157.559 33.28%
2021 18.057.994 16.06%
2022 18.678.259 3.32%
2023 13.711.870 -36.22%
2023 15.896.443 13.74%
2024 40.814.265 61.05%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kiora Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2012 37.155.750
2013 38.979.818 4.68%
2014 41.432.683 5.92%
2015 3.420.935 -1111.15%
2016 10.060.023 65.99%
2017 16.232.314 38.02%
2018 5.344.350 -203.73%
2019 3.490.059 -53.13%
2020 8.158.018 57.22%
2021 8.833.380 7.65%
2022 7.270.659 -21.49%
2023 7.602.216 4.36%
2023 7.792.474 2.44%
2024 7.712.592 -1.04%

Kiora Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.91
Net Income per Share
0.77
Price to Earning Ratio
4.48x
Price To Sales Ratio
0.63x
POCF Ratio
3
PFCF Ratio
2.16
Price to Book Ratio
0.43
EV to Sales
0.23
EV Over EBITDA
0.38
EV to Operating CashFlow
0.78
EV to FreeCashFlow
0.79
Earnings Yield
0.22
FreeCashFlow Yield
0.46
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
11.71
Graham NetNet
5.48

Income Statement Metrics

Net Income per Share
0.77
Income Quality
1.5
ROE
0.16
Return On Assets
0.08
Return On Capital Employed
0.07
Net Income per EBT
0.97
EBT Per Ebit
1.14
Ebit per Revenue
0.18
Effective Tax Rate
1.05

Margins

Sales, General, & Administrative to Revenue
0.31
Research & Developement to Revenue
0.28
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.99
Operating Profit Margin
0.18
Pretax Profit Margin
0.2
Net Profit Margin
0.2

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.15
Free CashFlow per Share
1.14
Capex to Operating CashFlow
0.01
Capex to Revenue
0
Capex to Depreciation
0.96
Return on Invested Capital
-0
Return on Tangible Assets
0.1
Days Sales Outstanding
82.23
Days Payables Outstanding
1161.68
Days of Inventory on Hand
0
Receivables Turnover
4.44
Payables Turnover
0.31
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
6,67
Book Value per Share
7,94
Tangible Book Value per Share
5.83
Shareholders Equity per Share
7.94
Interest Debt per Share
0.03
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.67
Current Ratio
19.22
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
39122008
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.22
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kiora Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Kiora Pharmaceuticals, Inc. Profile

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

CEO
Dr. Brian M. Strem Ph.D.
Employee
12
Address
1371 East 2100 South
Salt Lake City, 84105

Kiora Pharmaceuticals, Inc. Executives & BODs

Kiora Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Dr. Eric J. Daniels M.B.A., M.D.
Chief Development Officer
70
2 Dr. Brian M. Strem Ph.D.
President, Chief Executive Officer & Director
70
3 Ms. Melissa Tosca CPA
Chief Financial Officer
70
4 Dr. Stefan Sperl Ph.D.
Executive Vice President of CMC & Operations
70

Kiora Pharmaceuticals, Inc. Competitors